Mar 6 2006
Findings from the M.O.R.E. (Measuring Outcomes in A Real World Experience) Trial presented at the 64th annual meeting of the American Academy of Dermatology (AAD) show that Differin Gel 0.1% is a topical retinoid preparation that, when combined with other acne products, dramatically improves the efficacy of an acne regimen.
The M.O.R.E. Trial was conducted by over 400 dermatologists from across the U.S. to investigate the efficacy of Differin Gel 0.1% as add-on therapy or first-line combination therapy in moderate-to-moderately severe acne. The study also evaluated patient satisfaction and tolerability with Differin Gel 0.1% as part of an acne regimen.
"What's significant about the M.O.R.E. Trial is that many different treatment strategies are represented; therefore the trial is representative of the real world. Differin Gel 0.1%, when combined with many different products, yielded reliable improvements with excellent tolerability and patient satisfaction and can be regarded as an ideal topical retinoid preparation," said John E. Wolf, Jr. MD, Professor and Chairman at Baylor College of Medicine's department of Dermatology and a member of the steering committee for the trial.
Overall, results showed an 86% satisfaction rate among patients treated with Differin Gel 0.1% as part of an acne regimen. A dramatic reduction in comedones and inflammatory lesions (65%) was seen during the 12-week treatment with Differin Gel 0.1%, and Differin Gel 0.1% was very well tolerated by the participants, with less than 6% of subjects reporting any adverse events. The majority of patients (64%) also found Differin Gel 0.1% to be superior to other acne treatments when used in combination therapy.
"The effects of acne can be physically and emotionally scarring and can negatively impact a patient's quality of life. Often, prescribing treatment is challenging because of the differences in efficacy and tolerability among treatments. The M.O.R.E. data provides valuable insights for future approaches to acne treatment," said Dr. Wolf.